文献速递妇科

术前免疫组化标志物在子宫内膜癌ESMO-ESGO-ESTRO风险分类之外的预后价值

Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2021-04-12

本研究为ENITEC多中心回顾性研究,纳入763例子宫内膜癌患者,分析术前p53、L1CAM、ER、PR免疫组化表达与ESMO-ESGO-ESTRO风险分类、淋巴结状态及结局的关系。中位随访5.5年,异常表达与更高风险组相关,p53异常、ER/PR阴性及高风险组独立关联疾病特异性生存下降,异常表达合并淋巴结转移者结局最差。

要点

  • 术前p53/L1CAM/ER/PR免疫组化异常与更高ESMO-ESGO-ESTRO风险组相关。
  • p53异常、ER/PR阴性及高风险组独立关联疾病特异性生存下降。
  • 免疫组化异常合并淋巴结转移者结局最差,可指导手术分期和辅助治疗。

核心结论

  • 术前免疫组化标志物在ESMO-ESGO-ESTRO风险分类和淋巴结状态之外具有重要预后价值。

研究设计与样本

  • ENITEC多中心回顾性研究,纳入763例子宫内膜癌患者,中位随访5.5年。
  • 分析术前p53、L1CAM、ER、PR免疫组化表达,关联风险分类、淋巴结状态和结局。

主要发现

  • p53异常112例(14.7%),L1CAM异常79例(10.4%),ER阴性76例(10.0%),PR阴性138例(18.1%)。
  • 异常表达与更高风险分类组显著相关,并在「高及晚期/转移」风险组内联合关联最差结局。
  • 多因素分析中p53异常、ER/PR阴性及ESMO-ESGO-ESTRO「高及晚期/转移」独立关联疾病特异性生存下降。
  • 免疫组化异常合并淋巴结转移者结局最差;淋巴结转移且免疫组化正常者与无淋巴结转移且免疫组化异常者结局相当。

临床怎么用

  • p53/L1CAM/ER/PR表达可作为手术分期的指示指标。
  • 可将免疫组化标志物纳入ESMO-ESGO-ESTRO风险分类以细化选择性辅助治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Pre-operative immunohistochemical (IHC) biomarkers are not incorporated in endometrial cancer (EC) risk classification. We aim to investigate the added prognostic relevance of IHC biomarkers to the ESMO-ESGO-ESTRO risk classification and lymph node (LN) status in EC. METHODS: Retrospective multicenter study within the European Network for Individualized Treatment of Endometrial Cancer (ENITEC), analyzing pre-operative IHC expression of p53, L1 cell-adhesion molecule (L1CAM), estrogen receptor (ER) and progesterone receptor (PR), and relate to ESMO-ESGO-ESTRO risk groups, LN status and outcome. RESULTS: A total of 763 EC patients were included with a median follow-up of 5.5-years. Abnormal IHC expression was present for p53 in 112 (14.7%), L1CAM in 79 (10.4%), ER- in 76 (10.0%), and PR- in 138 (18.1%) patients. Abnormal expression of p53/L1CAM/ER/PR was significantly related with higher risk classification groups, and combined associated with the worst outcome within the 'high and advanced/metastatic' risk group. In multivariate analysis p53-abn, ER/PR- and ESMO-ESGO-ESTRO 'high and advanced/metastatic' were independently associated with reduced disease-specific survival (DSS). Patients with abnormal IHC expression and lymph node metastasis (LNM) had the worst outcome. Patients with LNM and normal IHC expression had comparable outcome with patients without LNM and abnormal IHC expression. CONCLUSION: The use of pre-operative IHC biomarkers has important prognostic relevance in addition to the ESMO-ESGO-ESTRO risk classification and in addition to LN status. For daily clinical practice, p53/L1CAM/ER/PR expression could serve as indicator for surgical staging and refine selective adjuvant treatment by incorporation into the ESMO-ESGO-ESTRO risk classification.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Vrede SW, van Weelden WJ, Visser NCM, et al. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer. Gynecol Oncol. 2021. PMID: 33858677. doi:10.1016/j.ygyno.2021.03.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。